Dividendos de Dyadic International

Dividendo controles de criterios 0/6

Dyadic International no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.9%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-US$0.23
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Is Dyadic International (NASDAQ:DYAI) In A Good Position To Deliver On Growth Plans?

Mar 14

Is Dyadic International (NASDAQ:DYAI) In A Good Position To Invest In Growth?

Oct 28

Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation

Jun 21

We're Hopeful That Dyadic International (NASDAQ:DYAI) Will Use Its Cash Wisely

Oct 05

Dyadic collaborates with Syngene International to develop a COVID-19 vaccine candidate

May 26

We're Not Very Worried About Dyadic International's (NASDAQ:DYAI) Cash Burn Rate

May 03

Dyadic International's (NASDAQ:DYAI) Wonderful 318% Share Price Increase Shows How Capitalism Can Build Wealth

Feb 22

Dyadic International (NASDAQ:DYAI) Is In A Good Position To Deliver On Growth Plans

Jan 18

Do Insiders Own Lots Of Shares In Dyadic International, Inc. (NASDAQ:DYAI)?

Dec 10

Dyadic International reports Q3 results

Nov 12

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de DYAI han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de DYAI han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Dyadic International vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de DYAI con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (DYAI)	n/a
Suelo de mercado 25% (US)	1.5%
Techo de mercado 25% (US)	4.8%
Media de la industria (Biotechs)	2.9%
Previsión de analistas en 3 años (DYAI)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de DYAI en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de DYAI en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de DYAI para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que DYAI no ha comunicado ningún pago.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Dividendos de Dyadic International

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Dyadic International, Inc., Annual General Meeting, Jun 11, 2024

Consensus EPS estimates fall by 159%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dyadic International, Inc. Announces Management Changes

Dyadic International, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Dyadic International, Inc. Announces Top-Line Results from Its Successful Phase 1 Clinical Trial for A First-In-Human Filamentous Fungal-Based Vaccine Candidate

New minor risk - Profitability

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates increase by 25%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Dyadic International, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Dyadic International, Inc Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate

Consensus revenue estimates increase by 74%

First quarter 2023 earnings released: US$0.033 loss per share (vs US$0.088 loss in 1Q 2022)

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Is Dyadic International (NASDAQ:DYAI) In A Good Position To Deliver On Growth Plans?

Dyadic International, Inc. Initiates Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

An unknown buyer acquired 1.99% stake in Alphazyme LLC from Dyadic International, Inc. (NasdaqCM:DYAI) for $1.27 million.

Consensus forecasts updated

Insufficient new directors

Consensus revenue estimates fall by 53%

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for Dyai-100 Covid-19 Recombinant Protein Rbd Booster Vaccine Candidate

Is Dyadic International (NASDAQ:DYAI) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 31%

Forecast to breakeven in 2023

Dyadic International, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation

Consensus forecasts updated

Price target decreased to US$7.50

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Dyadic International, Inc. Announces Successful Toxicology Data Published in Toxicologic Pathology

Insufficient new directors

Dyadic International, Inc. Announces Executive Changes

Consensus revenue estimates fall by 42%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Dyadic International, Inc. Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

Dyadic International, Inc. Announces A National Institute for Innovation in Manufacturing Biopharmaceuticals Coronavirus Grant Under the White House’s American Rescue Plan

Forecast to breakeven in 2023

Price target decreased to US$8.50

Third quarter 2021 earnings released: US$0.061 loss per share (vs US$0.091 loss in 3Q 2020)

We're Hopeful That Dyadic International (NASDAQ:DYAI) Will Use Its Cash Wisely

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.097 loss in 2Q 2020)

Dyadic International, Inc.(NasdaqCM:DYAI) dropped from Russell 3000E Value Index

Chief Financial Officer recently bought US$59k worth of stock

Dyadic collaborates with Syngene International to develop a COVID-19 vaccine candidate

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.081 loss in 1Q 2020)

We're Not Very Worried About Dyadic International's (NASDAQ:DYAI) Cash Burn Rate

Consensus forecasts updated

Full year 2020 earnings released: US$0.34 loss per share (vs US$0.31 loss in FY 2019)

Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100

Dyadic International's (NASDAQ:DYAI) Wonderful 318% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day high: US$6.79

Independent Director exercised options to buy US$290k worth of stock.

Dyadic International, Inc. Enters Collaboration with Turtle Tree Scientific

Dyadic International (NASDAQ:DYAI) Is In A Good Position To Deliver On Growth Plans

Dyadic International, Inc. Appoints Patrick Lucy to its Board of Directors

New 90-day low: US$5.57

Do Insiders Own Lots Of Shares In Dyadic International, Inc. (NASDAQ:DYAI)?

Third quarter 2020 earnings released: US$0.091 loss per share

Earnings beat expectations, revenue disappoints

Dyadic International reports Q3 results

Dyadic International, Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day low: US$6.85

Dyadic International, Inc. Announces Update on its Coronavirus (Covid-19) Programs Globally

New 90-day low: US$6.91

New 90-day low: US$7.22

Dyadic International, Inc. completed the acquisition of CCP Worldwide, Inc. in a reverse merger transaction.

Dyadic International, Inc. Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

First half earnings released

Dyadic International, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas